Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience

Leuk Lymphoma. 2021 Sep;62(9):2177-2183. doi: 10.1080/10428194.2021.1897806. Epub 2021 Mar 29.

Abstract

Few publications exist concerning allogeneic hematopoietic cell transplant (alloHCT) outcomes in non-Japanese patients with HTLV-1-associated ATLL. We detail the patient and disease characteristics, transplant approach, and clinical outcomes in 17 patients with ATLL at our institution who underwent alloHCT. We report favorable outcomes, with 8/17 in ongoing remission, 2/17 with prolonged (>6 years) disease-free survival, and a low incidence of transplant-related mortality (2/17). These results validate the feasibility and efficacy of alloHCT in non-Japanese patients with ATLL.

Keywords: Adult T-cell leukemia lymphoma; allogeneic stem cell transplantation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Human T-lymphotropic virus 1*
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell* / diagnosis
  • Leukemia-Lymphoma, Adult T-Cell* / therapy
  • Lymphoma*